Welcome to Etubics
Etubics Corporation is a Seattle based biopharmaceutical company developing targeted immunotherapies and vaccine products for a wide range of resilient diseases. Etubics patent-protected technology has been proven to be safer, more efficient and more effective than current vectored vaccines and gene delivery platforms.
We specialize in developing innovative immunotherapies and vaccines utilizing our exclusive next-generation viral vector gene delivery technology and our patented manufacturing cell line, together the Etubics Platform.
The Etubics Platform delivers a long lasting “active” immune response against diseases and induces both cell mediated immunity and antibody. The Etubics Platform provides the following capabilities:
|Next Generation Vaccines||What’s New|
Etubics is developing innovative immunotherapies and vaccines, utilizing our proprietary gene delivery platform and our patented human E.C7 human cell line, together the Etubics Platform.
The Etubics Platform provides the following capabilities: a long lasting “active” immune response against diseases and induces both cell mediated immunity and antibody.
Etubics Corporation has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute, a part of the National Institutes of Health, to investigate a multi-targeted immunotherapy approach containing three tumor-associated antigens including ETBX-011. These three antigens are highly expressed in various human carcinomas and the ability to simultaneously target all three could be of significant clinical benefit in terms of overall survival of cancer patients.
Oncotarget recently published an article entitled “The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic” which details the collaborative work of Etubics and the National Cancer Institute on a multi-targeted immunotherapy called Tri-Ad5. The Tri-Ad5 will be investigated as a therapeutic modality to induce immune responses to a diverse range of human cancer targets. The article is available online at Oncotarget.
Cancer Gene Therapy has published Etubics’ article entitled “An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.” In this article data demonstrating the synergistic effect of combining an immunotherapy against human papilloma virus (HPV) (Ad5 [E1-, E2b-]-E6/E7) with programmed death-ligand 1 (PD-1) blockade. The article is available online at Nature.
Last Updated: November 2015